Two Mpox vaccines deployed in Congo — Precision Vaccination News

(Accurate Vaccination News)

Since the beginning of 2024, more than 20,000 cases of ampox have been reported in the Democratic Republic of the Congo (DRC), with over 1,000 deaths, mainly affecting children.

In June 2024, the US CDC issued a Level 2 alert, reporting ampox outbreaks in 25 of the 26 DTC provinces, including urban areas.

According to media sources, authorities in the DRC have approved the use of two new vaccines in response to the outbreak. On June 28, 2024, it was reported that emergency use authorization was issued for the Geneos® vaccine developed by Bavarian Nordic and LC16 produced by KM Biologics.

LC16 is a third-generation live attenuated vaccine containing live vaccinia virus (LC16M8 strain), used for the prevention of smallpox and ampox.

The DRC decision is taken following rigorous evaluation by relevant authorities and stakeholders involved in the authorisation process.

JYNNEOS (MVA-BN®, IMVAMUNE®) is a two-dose vaccine based on live, attenuated vaccinia virus, modified vaccinia Ankara, and is offered in the United States starting in May 2022.

Leave a Comment

“The Untold Story: Yung Miami’s Response to Jimmy Butler’s Advances During an NBA Playoff Game” “Unveiling the Secrets: 15 Astonishing Facts About the PGA Championship”